Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Incidence and Clinical Outcomes of Non-endometrioid Carcinoma of Endometrium: Siriraj Hospital Experience

  • Jaishuen, Atthapon (Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Kunakornporamat, Kate (Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Viriyapak, Boonlert (Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Benjapibal, Mongkol (Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Chaopotong, Pattama (Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Petsuksiri, Janjira (Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Therasakvichya, Suwanit (Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University)
  • Published : 2014.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: To study the incidence of non-endometrioid carcinoma of endometrium and compare the clinical characteristics and treatment outcomes with endometrioid carcinoma patients. Materials and Methods: This study included 236 patients with endometrial carcinoma at Siriraj Hospital whom were diagnosed and treated from 2003 through 2006. The clinical characteristics, pathological features, treatment and clinical outcomes were collected from the medical records. The 5-year survival was calculated according to 2009 FIGO staging. Results: Non-endometrioid carcinoma of endometrium accounted for 10.2% of all endometrial carcinomas (24/236 patients). The 5-year survival rate was significantly lower in the non-endometrioid group compared to the endometrioid group (77.3% vs 96%, p<0.001) and clinical data pointed to greater malignancy. Conclusions: Non-endometrioid carcinoma of endometrium is relative rare but is more aggressive, has more distant metastasis at diagnosis with a worse survival rate than endometrioid carcinoma. Only patients in stage IA with no residual disease on a hysterectomy specimen may not need adjuvant treatment.

Keywords

References

  1. Barney BM, Petersen IA, Mariani A, et al (2013). The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys, 85, 109-15. https://doi.org/10.1016/j.ijrobp.2012.03.011
  2. Benedetti Panici P, Basile S, Maneschi F, et al (2008). Systematic pelvic lymphadenectomy vs. no lymphadenectomy in earlystage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst, 100, 1707-16. https://doi.org/10.1093/jnci/djn397
  3. Bjorge T, Engeland A, Tretli S, Weiderpass E (2007). Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer, 120, 378-83. https://doi.org/10.1002/ijc.22260
  4. Boruta DM, Gehrig PA, Fader AN, Olawaiye AB (2009). Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecologic Oncol, 115, 142-53. https://doi.org/10.1016/j.ygyno.2009.06.011
  5. Chan JK, Cheung MK, Huh WK, et al (2006). Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer, 107, 1823-30. https://doi.org/10.1002/cncr.22185
  6. Chang-Halpenny CN, Natarajan S, Hwang-Graziano J (2013). Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy. Gynecol Oncol, 131, 598-603. https://doi.org/10.1016/j.ygyno.2013.10.010
  7. Creasman WT, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet, 95, 105-43. https://doi.org/10.1016/S0020-7292(06)60031-3
  8. Desai NB, Kiess AP, Kollmeier MA, et al (2013). Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. Gynecol Oncol, 131, 604-8. https://doi.org/10.1016/j.ygyno.2013.09.019
  9. Fader AN, Boruta D, Olawaiye AB, Gehrig PA (2010). Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol, 22, 21-9. https://doi.org/10.1097/GCO.0b013e328334d8a3
  10. Ferlay J, Shin HR, Bray F, et al (2008). "GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer.
  11. Gehrig PA, Van Le L, Fowler WC Jr (2003). The role of omentectomy during the surgical staging of uterine serous carcinoma. Int J Gynecol Cancer, 13, 212-5.
  12. Hamilton CA, Cheung MK, Osann K, et al (2006). Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer, 94, 642-6.
  13. Jhingran A, Ramondetta LM, Bodurka DC, et al (2013). A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol, 129, 304-9. https://doi.org/10.1016/j.ygyno.2013.01.025
  14. Kelly MG, O'Malley D M, Hui P, et al (2005). Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol, 98, 353-9. https://doi.org/10.1016/j.ygyno.2005.06.012
  15. Khunhaprema T, Attasara P, Sriplung H, et al (2012). Cancer in Thailand. Volume VI, 2004-2006. Bangkok, National Cancer Institute, Department od Medical Service, Ministry of Public Health.
  16. Kim HJ, Kim TJ, Lee YY, et al (2013). A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system. J Gynecol Oncol, 24, 120-7. https://doi.org/10.3802/jgo.2013.24.2.120
  17. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009). Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet, 373, 125-36. https://doi.org/10.1016/S0140-6736(08)61766-3
  18. Olawaiye AB, Boruta DM (2009). Management of women with clear cell endometrial cancer A Society of Gynecologic Oncology (SGO) review. Gynecologic Oncology, 113, 277-83. https://doi.org/10.1016/j.ygyno.2009.02.003
  19. Siegel R, Naishadham D and Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  20. Slomovitz BM, Burke TW, Eifel PJ, et al (2003). Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol, 91, 463-9. https://doi.org/10.1016/j.ygyno.2003.08.018
  21. Todo Y, Kato H, Kaneuchi M, et al (2010). Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet, 376, 1165-72.
  22. Wilairat W, Benjapibal M (2012). Presence of anemia and poor prognostic factors in patients with endometrial carcinoma. Asian Pac J Cancer Prev, 13, 3187-90. https://doi.org/10.7314/APJCP.2012.13.7.3187
  23. Wilson TO, Podratz KC, Gaffey TA, et al (1990). Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol, 162, 418-23. https://doi.org/10.1016/0002-9378(90)90399-R

Cited by

  1. Comparison of Myometrial Invasion and Tumor Free Distance from Uterine Serosa in Endometrial Cancer vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.519